Floor J.E. Lubberman

The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study)

Floor J.E. Lubberman, Hans Gelderblom, Paul Hamberg et al. · Clinical Pharmacology & Therapeutics · 2019 · 37 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Analytical challenges in quantifying abiraterone with LC–MS/MS in human plasma

Guillemette E. Benoist, Eric van der Meulen, Floor J.E. Lubberman et al. · Biomedical Chromatography · 2017 · 26 citations · Full text

Pharmacy, Pharmacology, Analytical Chemistry +16

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure

Stefanie D. Krens, Floor J.E. Lubberman, Marthe van Egmond et al. · International Journal of Cancer · 2021 · 15 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics

Floor J.E. Lubberman, Guillemette E. Benoist, Winald R. Gerritsen et al. · Cancer Chemotherapy and Pharmacology · 2019 · 13 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

Maud B. A. van der Kleij, Niels A.D. Guchelaar, Marinda Meertens et al. · British Journal of Cancer · 2024 · 10 citations · Full text

Pharmacy, Oncology, Pharmacology +13